Form 4: Foghorn Therapeutics Director Reports Stock Option Grant

Foghorn Therapeutics Director B. Lynne Parshall reported the acquisition of stock options, indicating a potential future stake in the company.

Summary

• B. Lynne Parshall, a Director at Foghorn Therapeutics Inc. (FHTX), has reported the acquisition of stock options.
• The transaction, dated June 24, 2026, involves 28,000 stock options with an exercise price of $4.08 per share.
• These options are exercisable starting June 23, 2036, and have a term until June 23, 2036.
• The options vest in full on the first anniversary of the grant date, contingent upon Ms. Parshall's continued service on the board.
• This filing is made under Section 16(a) of the Securities Exchange Act of 1934, which requires reporting of insider transactions.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive filing, as it reflects standard insider compensation practices and a long-term commitment from a director, without providing new operational or financial performance data.

Positives

• Director B. Lynne Parshall has been granted stock options, aligning her interests with the company's long-term performance.
• The grant of options suggests management's confidence in the future value of Foghorn Therapeutics.

Risks

• The vesting of options is contingent on continued service, meaning a departure from the board would forfeit these options.
• The long exercise date (June 23, 2036) indicates a long-term incentive structure, with potential for significant value fluctuation before exercise.

Future Outlook

The filing itself does not contain forward-looking statements or guidance. However, the grant of stock options with a distant exercise date implies a long-term positive outlook for the company's stock performance.

Industry Context

StockSavvy.ai notes that the granting of stock options to directors is a common practice in the biotechnology and pharmaceutical sectors, serving as a key incentive for leadership to drive long-term value creation and align with shareholder interests.

Corporate Governance

Stakeholder Impact

• Shareholders: The granting of options to a director aligns their interests with shareholders, potentially leading to decisions that enhance long-term shareholder value.
• Employees: Standard compensation practice that may indirectly signal company stability and future growth prospects.
• Management: Reinforces the incentive structure for directors to remain with the company and contribute to its success.

Next Steps

• B. Lynne Parshall will continue to serve as a Director of Foghorn Therapeutics Inc.
• The stock options will vest on June 24, 2027, subject to continued service.
• The stock options will become exercisable on June 23, 2036, and expire on June 23, 2036.

Key Dates

Keywords

Foghorn Therapeutics, FHTX, Form 4, Stock Options, Insider Trading, Director, SEC Filing, Beneficial Ownership, Securities Exchange Act